{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fu CHY"],"funding":["Fok Ying Tong Education Foundation","NIBIB NIH HHS","Lister Institute of Preventive Medicine","NIA NIH HHS","NIDA NIH HHS","U.S. Department of Health &amp; Human Services | NIH | National Institute on Aging","NIMH NIH HHS","National Natural Science Foundation of China","U.S. Department of Health &amp; Human Services | NIH | National Institute on Drug Abuse","U.S. Department of Health &amp; Human Services | NIH | National Institute of Mental Health","Lundbeck Foundation","U.S. Department of Health &amp; Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering","Canadian Institute for Advanced Research","Medical Research Council","National Institute for Health Research (NIHR)","Lundbeckfonden","Wellcome Trust","Ontario Brain Institute","Gouvernement du Canada | Canadian Institutes of Health Research","NIGMS NIH HHS"],"pagination":["164-176"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11211072"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["2(2)"],"pubmed_abstract":["Major depressive disorder (MDD) is a heterogeneous clinical syndrome with widespread subtle neuroanatomical correlates. Our objective was to identify the neuroanatomical dimensions that characterize MDD and predict treatment response to selective serotonin reuptake inhibitor (SSRI) antidepressants or placebo. In the COORDINATE-MDD consortium, raw MRI data were shared from international samples (<i>N</i> = 1,384) of medication-free individuals with first-episode and recurrent MDD (<i>N</i> = 685) in a current depressive episode of at least moderate severity, but not treatment-resistant depression, as well as healthy controls (<i>N</i> = 699). Prospective longitudinal data on treatment response were available for a subset of MDD individuals (<i>N</i> = 359). Treatments were either SSRI antid"],"journal":["Nature. Mental health"],"pubmed_title":["Neuroanatomical dimensions in medication-free individuals with major depressive disorder and treatment response to SSRI antidepressant medications or placebo."],"pmcid":["PMC11211072"],"funding_grant_id":["R37MH101495","81621003","RF1 AG054409","5R01MH101472","R01MH098099","U01 MH092250","R01 AG066650","G0601526","81820108018","82122035","U01MH092221","R279-2018-1145","MR/T017538/1","R01 EB022573","151023","R01 MH101472","R01MH125850","173096","P50MH077083","R01 MH080880","216767/Z/19/Z","U01 AG068057","220857/Z/20/Z","R01MH134236","R01 MH098099","R01 MH134236","R01 MH125850","R01 MH123550","G0701421","U01 DA041089","1RO1MH080880","U01 MH092221","K01MH096077","P20 GM121312","R01 MH112070","K01 MH096077","G0902304","R01AG066650","R37 MH101495","R01EB022573","P50 MH077083"],"pubmed_authors":["Hassel S","Qiu J","Craighead WE","Wise T","Choi KS","Shou H","Elliott R","Frey BN","Fu CHY","Whalley HC","Davatzikos C","Rotzinger S","Yan CG","Fatt CC","Sacchet MD","Chen T","Paulus MP","Erus G","Godlewska BR","Ho K","Deakin JFW","Tosun D","Gotlib IH","Antoniades M","Dunlop BW","Knudsen GM","Frokjaer VG","Ganz M","Garcia JA","Stolicyn A","Trivedi MH","Gong Q","Qin K","Savitz J","Young AH","Anderson IM","McIntosh AM","Arnone D","Strigo I","Victor TA","Fan Y","Zahn R","Strother SC","Wei D","Singh A","Mayberg HS","Kennedy SH","Arnott SR","Harmer CJ"],"additional_accession":[]},"is_claimable":false,"name":"Neuroanatomical dimensions in medication-free individuals with major depressive disorder and treatment response to SSRI antidepressant medications or placebo.","description":"Major depressive disorder (MDD) is a heterogeneous clinical syndrome with widespread subtle neuroanatomical correlates. Our objective was to identify the neuroanatomical dimensions that characterize MDD and predict treatment response to selective serotonin reuptake inhibitor (SSRI) antidepressants or placebo. In the COORDINATE-MDD consortium, raw MRI data were shared from international samples (<i>N</i> = 1,384) of medication-free individuals with first-episode and recurrent MDD (<i>N</i> = 685) in a current depressive episode of at least moderate severity, but not treatment-resistant depression, as well as healthy controls (<i>N</i> = 699). Prospective longitudinal data on treatment response were available for a subset of MDD individuals (<i>N</i> = 359). Treatments were either SSRI antid","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-06-01T15:33:58.909Z","creation":"2026-04-08T13:39:38.39Z"},"accession":"S-EPMC11211072","cross_references":{"pubmed":["38948238"],"doi":["10.1038/s44220-023-00187-w"]}}